CA1251209A - DISHYDROPYRIDAZINONE DERIVATIVES - Google Patents

DISHYDROPYRIDAZINONE DERIVATIVES

Info

Publication number
CA1251209A
CA1251209A CA000471594A CA471594A CA1251209A CA 1251209 A CA1251209 A CA 1251209A CA 000471594 A CA000471594 A CA 000471594A CA 471594 A CA471594 A CA 471594A CA 1251209 A CA1251209 A CA 1251209A
Authority
CA
Canada
Prior art keywords
compounds
hydrogen
formula
dihydropyridazinone derivatives
dihydropyridazinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000471594A
Other languages
English (en)
French (fr)
Other versions
CA1260471C (enExample
Inventor
Robert A Slater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline & French Laboratories Ltd
Original Assignee
Smith Kline & French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline & French Laboratories Ltd filed Critical Smith Kline & French Laboratories Ltd
Priority to CA000581012A priority Critical patent/CA1260471A/en
Publication of CA1251209A publication Critical patent/CA1251209A/en
Application granted granted Critical
Publication of CA1260471C publication Critical patent/CA1260471C/xx
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
CA000471594A 1984-01-13 1985-01-07 DISHYDROPYRIDAZINONE DERIVATIVES Expired CA1251209A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000581012A CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA000581012A Division CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Publications (2)

Publication Number Publication Date
CA1251209A true CA1251209A (en) 1989-03-14
CA1260471C CA1260471C (enExample) 1989-09-26

Family

ID=10554924

Family Applications (2)

Application Number Title Priority Date Filing Date
CA000471594A Expired CA1251209A (en) 1984-01-13 1985-01-07 DISHYDROPYRIDAZINONE DERIVATIVES
CA000581012A Expired CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA000581012A Expired CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Country Status (31)

Country Link
US (1) US4654342A (enExample)
EP (1) EP0150937B1 (enExample)
JP (3) JPS60158181A (enExample)
KR (1) KR920006781B1 (enExample)
CN (1) CN85101722A (enExample)
AT (1) ATE37179T1 (enExample)
AU (1) AU572252B2 (enExample)
CA (2) CA1251209A (enExample)
CS (1) CS248731B2 (enExample)
DD (1) DD231350A5 (enExample)
DE (1) DE3564941D1 (enExample)
DK (1) DK162519C (enExample)
ES (3) ES8607949A1 (enExample)
FI (1) FI850140A7 (enExample)
GB (1) GB8400863D0 (enExample)
GR (1) GR850068B (enExample)
HU (1) HU193591B (enExample)
IE (1) IE57969B1 (enExample)
IL (1) IL74031A (enExample)
JO (1) JO1351B1 (enExample)
MY (1) MY100124A (enExample)
NO (1) NO850129L (enExample)
NZ (1) NZ210816A (enExample)
PH (1) PH22136A (enExample)
PL (1) PL147123B1 (enExample)
PT (1) PT79819B (enExample)
RO (1) RO92607A (enExample)
SU (1) SU1396963A3 (enExample)
WO (1) WO1985003076A1 (enExample)
ZA (1) ZA85251B (enExample)
ZW (1) ZW385A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
US6562821B2 (en) 2001-02-27 2003-05-13 Mitokor Aryl-N-cyanoguanidines and methods related thereto
PL369738A1 (en) * 2001-11-05 2005-05-02 Merck Patent Gmbh Hydrazono-malonitriles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
DK1951227T3 (en) * 2005-11-14 2017-07-10 Boehringer Ingelheim Vetmedica Gmbh APPLICATION OF PIMOBENDAN TO TREAT ASYMPTOMATIC (OCCULT) HEART FAILURE
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
DE3263497D1 (en) * 1981-03-04 1985-06-20 Ciba Geigy Ag Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones

Also Published As

Publication number Publication date
AU3761185A (en) 1985-07-18
US4654342A (en) 1987-03-31
IE57969B1 (en) 1993-06-02
FI850140L (fi) 1985-07-14
EP0150937A3 (en) 1985-08-21
IE850069L (en) 1985-07-13
PT79819B (en) 1987-01-07
CS248731B2 (en) 1987-02-12
KR850005417A (ko) 1985-08-26
FI850140A7 (fi) 1985-07-14
JPS63313775A (ja) 1988-12-21
MY100124A (en) 1989-12-18
AU572252B2 (en) 1988-05-05
JO1351B1 (en) 1986-11-30
PL147123B1 (en) 1989-04-29
ES8607949A1 (es) 1986-06-01
ES8706645A1 (es) 1987-07-01
EP0150937B1 (en) 1988-09-14
ES554965A0 (es) 1987-07-01
NO850129L (no) 1985-07-15
DE3564941D1 (en) 1988-10-20
IL74031A0 (en) 1985-04-30
CA1260471C (enExample) 1989-09-26
KR920006781B1 (ko) 1992-08-17
NZ210816A (en) 1987-06-30
DK9185D0 (da) 1985-01-08
CA1260471A (en) 1989-09-26
SU1396963A3 (ru) 1988-05-15
DK9185A (da) 1985-07-14
FI850140A0 (fi) 1985-01-11
ES8703846A1 (es) 1987-03-01
WO1985003076A1 (en) 1985-07-18
IL74031A (en) 1988-07-31
HUT37128A (en) 1985-11-28
RO92607A (ro) 1987-11-30
CN85101722A (zh) 1987-01-31
DD231350A5 (de) 1985-12-24
EP0150937A2 (en) 1985-08-07
HU193591B (en) 1987-11-30
PT79819A (en) 1985-02-01
PL251516A1 (en) 1985-12-17
JPS63313776A (ja) 1988-12-21
ZA85251B (en) 1986-08-27
JPS60158181A (ja) 1985-08-19
ES549629A0 (es) 1987-03-01
GB8400863D0 (en) 1984-02-15
DK162519C (da) 1992-03-30
GR850068B (enExample) 1985-05-03
PH22136A (en) 1988-06-01
ATE37179T1 (de) 1988-09-15
ES539446A0 (es) 1986-06-01
DK162519B (da) 1991-11-11
ZW385A1 (en) 1985-08-07

Similar Documents

Publication Publication Date Title
AU572252B2 (en) 5-methyl-4,5 dihydro-3(2h) pyridazinone derivatives
ES8706664A1 (es) Procedimiento para preparar compuestos carbostirilicos
AU553840B2 (en) Octahydrobenzo(f)quinoline compounds
ES8304567A1 (es) "un procedimiento para preparar nuevos derivados de la n-dihidrotiazolil-3-quinolein-carboxamida".
ES8404360A1 (es) Un procedimiento para preparar compuestos de cefem.
GB2115815B (en) Benzothiazoline compounds
IE811212L (en) Substituted phenoxy-aminopropanol derivatives
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure
ES8302719A1 (es) Un procedimiento para preparar compuestos de cefem
ES8102144A2 (es) Procedimiento para la preparacion de derivados de la isoqui-noleina

Legal Events

Date Code Title Description
MKEX Expiry